Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSP-3456
- Development stage
- Unknown
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DSP-3456 is an investigational oral small molecule developed by Sumitomo Pharma for the treatment of treatment-resistant depression (TRD). It acts as a negative allosteric modulator (NAM) of the metabotropic glutamate receptors 2 and 3 (mGluR2/3). By modulating these receptors, which normally inhibit glutamate release, DSP-3456 is designed to enhance glutamatergic neurotransmission and selectively activate the prefrontal cortex. This mechanism is hypothesized to yield rapid-acting antidepressant effects similar to ketamine but without the associated dissociative, psychotic, or cognitive side effects. The compound is currently in Phase 1 clinical development.
02
Targets
GRM3 (mGluR3)
Beyond the preview
Go deeper on DSP-3456.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSP-3456.